What Is Bioidentical Hormone Therapy for Men?
Bioidentical hormone therapy for men uses lab-synthesized hormones structurally identical to endogenous testosterone. Learn about FDA-approved options, dosing, risks, and monitoring.
Where Can I Get TRT? A Guide to Safe, Legal Options
Learn where to get testosterone replacement therapy (TRT) legally and safely, including telehealth clinics, urologists, endocrinologists, and compounding pharmacies.
Why Should Testosterone Pellets Be Avoided in Women?
Testosterone pellets deliver a fixed, non-adjustable dose of testosterone that commonly produces male-range blood levels in women. Here is what is established, what is plausible but unproven, and what alternatives have better evidence.
Januvia vs Metformin Cost: Price and Evidence Compared
Metformin costs $4-$20/month generic; Januvia runs $450-$550 branded. Metformin also has stronger long-term outcomes data, per major guidelines.
Metformin Geriatric (65+) Dosing: Evidence-Based Guide to Safe Prescribing
How to dose metformin safely in adults 65 and older. Covers renal-adjusted starting doses, titration schedules, eGFR thresholds, B12 monitoring, and deprescribing criteria backed by primary-source evidence.
Metformin Geriatric (65+) Monitoring: Lab Schedules, Dose Adjustments, and Safety Checks
Evidence-based monitoring guide for metformin in adults 65 and older. Covers renal function tracking, B12 screening, lactic acidosis risk, deprescribing criteria, and recommended lab intervals.
Does Humana Cover Metformin? Formulary Tiers, Prior Auth, and Appeal Steps
Find out whether Humana covers metformin for type 2 diabetes and off-label uses, which formulary tier it sits on, prior-authorization rules, and how to appeal a denial.
Metformin Mechanism of Action: The Full Molecular Pathway Explained
A physician-level breakdown of how metformin works, from mitochondrial Complex I inhibition and AMPK activation to hepatic glucose suppression, gut signaling, and microbiome remodeling.
Metformin Missed-Dose Protocol: What to Do When You Skip a Dose
Missing one metformin dose usually causes only a modest fasting glucose rise of 15 to 30 mg/dL, not a crisis. Never double up; repeated gaps raise HbA1c.
Metformin Patent Field & Generic Timeline
A detailed history of metformin patents, generic approvals, extended-release formulations, and the current competitive field for the world's most prescribed diabetes drug.
Metformin Safety Signals and FDA Actions: What Prescribers and Patients Should Know
Metformin and vitamin B12 deficiency: DPPOS found 4.3% deficiency vs 2.3% placebo; ADA advises periodic B12 checks. FDA boxed warning: lactic acidosis.
Switching From or To Metformin: Evidence-Based Protocols for Every Scenario
Clinical protocols for switching between metformin and other glucose-lowering drugs, including GLP-1 agonists, SGLT2 inhibitors, sulfonylureas, and insulin. Covers timing, dose bridging, and monitoring.
How to Safely Stop Methimazole (Tapazole): A Clinician-Guided Discontinuation Protocol
Evidence-based guide to safely discontinuing methimazole (Tapazole) for hyperthyroidism and Graves' disease, including taper schedules, lab monitoring, relapse predictors, and when definitive therapy may be preferred.
MK-677 (Ibutamoren) Cost vs. Alternatives in Class
A clinical comparison of MK-677 pricing against prescription GH secretagogues, injectable somatropin, and compounded peptide alternatives, with efficacy and safety data for each option.
MK-677 (Ibutamoren) Geriatric (65+) Monitoring: Lab Tests, Safety Checks, and Clinical Oversight
Evidence-based monitoring protocol for MK-677 (ibutamoren) use in adults 65 and older, covering IGF-1 tracking, glucose surveillance, edema assessment, and drug interaction screening.
MK-677 (Ibutamoren): History, Development, and Mechanism of Action
A clinical history of MK-677 (ibutamoren mesylate), from Merck's 1990s discovery program through Phase II trials, including its mechanism as an oral ghrelin receptor agonist and the research that shaped growth hormone secretagogue science.
MK-677 (Ibutamoren) Monitoring Schedule: Labs & Exams
Evidence-based monitoring schedule for MK-677 (ibutamoren) including IGF-1, fasting glucose, HbA1c, insulin, prolactin, and recommended exam intervals.
MK-677 (Ibutamoren) Off-Label Uses With Evidence Levels
A clinician-grade review of MK-677 (ibutamoren) off-label applications, including body composition, bone density, sleep quality, and sarcopenia, graded by strength of evidence from published trials.
MK-677 (Ibutamoren) Safety in Older Adults (50-64): What the Evidence Shows
A clinical review of MK-677 (ibutamoren) safety data for adults aged 50-64, covering insulin resistance, edema, cardiovascular risk, and GH/IGF-1 monitoring.
MK-677 (Ibutamoren) Pediatric Monitoring for Children Under 12
What clinical monitoring would need to look like if MK-677 (ibutamoren) were used off-label in a child under 12, including IGF-1 tracking, glucose surveillance, growth plate assessment, and the evidence gaps that make this an unapproved, unstudied use in this age group.
MK-677 (Ibutamoren) Pharmacogenomics: How Genetic Variability Shapes GH Secretagogue Response
A clinical deep dive into how polymorphisms in GHSR, GH1, IGF1, and CYP3A4 genes influence MK-677 (ibutamoren) efficacy, side-effect burden, and dosing considerations.
MK-677 (Ibutamoren) Storage, Stability & Shelf Life
Evidence-based guide to MK-677 (ibutamoren) storage conditions, chemical stability, degradation pathways, and shelf life. Covers temperature, light, humidity, and reconstitution handling.
MK-677 (Ibutamoren): Switching From or To Other GH Secretagogues
Clinical guidance on transitioning between MK-677 (ibutamoren) and other growth hormone secretagogues, including washout periods, IGF-1 monitoring, and protocol considerations.
MK-677 Dosing in Young Adults: Study Arms Are Not a Regimen
A study-arm replay for ibutamoren in young adults, showing why experimental doses, durations, and timing do not establish a recommended clinical regimen.
MOTS-c Adolescent (12 to 17) Dosing: What the Evidence Actually Shows
MOTS-c has no FDA-approved adolescent dosing. This guide covers the preclinical evidence, theoretical dose ranges from adult research protocols, and why no clinician should prescribe this peptide to minors outside a supervised trial.
MOTS-c Geriatric (65+) Monitoring: Lab Tests, Safety Checks, and Clinical Protocols
Evidence-based monitoring guide for MOTS-c mitochondrial peptide in adults 65 and older. Covers baseline labs, renal function tracking, glucose surveillance, drug interaction screening, and deprescribing considerations.
MOTS-c Dosing in Hepatic Impairment: What Clinicians Need to Know
Evidence-based guide to MOTS-c mitochondrial peptide dosing considerations in patients with hepatic impairment, covering mechanism, pharmacokinetics, safety, and clinical guidance.
MOTS-c Monitoring for Older Adults (50 to 64): Lab Panels, Safety Markers, and Clinical Checkpoints
Evidence-based monitoring guide for MOTS-c mitochondrial peptide use in adults aged 50 to 64, covering baseline labs, ongoing safety markers, cardiovascular risk, and metabolic tracking.
MOTS-c Patent Status and Generic Timeline: What Clinicians Need to Know
A clinical review of MOTS-c mitochondrial peptide intellectual property, patent filings, regulatory status, and projected generic availability for metabolic and longevity applications.
MOTS-c Pregnancy & Lactation Safety: What the Evidence Actually Shows
MOTS-c is an investigational mitochondrial peptide with no human pregnancy or lactation data. Learn what preclinical research reveals and why clinicians advise against use during pregnancy and breastfeeding.
MOTS-c Regulatory Status: Where This Mitochondrial Peptide Stands in the US, EU, Canada, and the UK
MOTS-c is not approved by the FDA, EMA, Health Canada, or MHRA. Learn the current regulatory status of this mitochondrial-derived peptide across major markets, what the science shows, and what that means for clinical access.
Mounjaro Adult (30-49) Dosing: Complete Tirzepatide Schedule, Titration, and Clinical Guide
Evidence-based guide to Mounjaro (tirzepatide) dosing for adults aged 30-49. Covers the full titration schedule from 2.5 mg to 15 mg, injection technique, missed-dose rules, and age-specific clinical considerations.
Does Aetna (CVS Health) Cover Mounjaro? Prior Authorization, Formulary Tier, and Appeal Steps
Aetna (CVS Health) covers Mounjaro (tirzepatide) for type 2 diabetes with prior authorization and step therapy. Learn formulary tier, PA criteria, appeal steps, and how to reduce out-of-pocket costs.
Does Anthem (Elevance Health) Cover Mounjaro?
Anthem (Elevance Health) covers Mounjaro for type 2 diabetes with prior authorization and step therapy. Learn formulary tier, PA criteria, appeal steps, and cost-saving options.
Does Cigna Cover Mounjaro? Prior Authorization, Formulary Tier, and Appeal Steps
Find out whether Cigna covers Mounjaro (tirzepatide) for type 2 diabetes and weight loss, including prior authorization criteria, formulary placement, step therapy rules, and how to appeal a denial.
Mounjaro Insurance Coverage, Cost and Alternatives Compared
Mounjaro costs about $1,023 monthly without insurance, similar to Ozempic but pricier than Trulicity. See coverage options and how efficacy compares.
Does Humana Cover Mounjaro? Formulary Tiers, Prior Auth, and Appeal Steps
Find out whether Humana covers Mounjaro (tirzepatide) for type 2 diabetes and weight loss, including formulary placement, prior-authorization criteria, step therapy rules, and how to appeal a denial.
Does Kaiser Permanente Cover Mounjaro? Prior Authorization, Formulary Tier, and Appeal Steps
Kaiser Permanente coverage for Mounjaro (tirzepatide) explained: formulary status, prior authorization criteria, step therapy requirements, manufacturer savings card rules, and how to appeal a denial.
Mounjaro Manufacturing, Supply & Shortage History
A clinical deep-dive into tirzepatide (Mounjaro) manufacturing processes, supply chain disruptions, FDA shortage listings, and Eli Lilly's capacity expansion timeline.
Does State Medicaid Cover Mounjaro? A State-by-State Breakdown
State Medicaid coverage for Mounjaro (tirzepatide) varies widely. Learn which states cover it for type 2 diabetes vs. weight loss, prior authorization requirements, step therapy rules, and how to appeal a denial.
Mounjaro Older Adult (50-64) Dosing: Tirzepatide Schedule, Titration, and Safety
Evidence-based guide to Mounjaro (tirzepatide) dosing for adults aged 50-64. Covers titration schedule, dose adjustments for kidney function and polypharmacy, and clinical trial data from SURPASS trials.
Mounjaro (Tirzepatide) Pregnancy and Lactation Safety
Evidence-based guide to tirzepatide (Mounjaro) safety during pregnancy and breastfeeding, including FDA labeling, animal data, washout timing, and what remains unknown.
Is Mounjaro an FDA-Inspected Medication? Approval Status
Mounjaro is FDA-approved (May 2022) for type 2 diabetes, plus approved by EMA, MHRA, and Health Canada. See exact approval dates by country.
Mounjaro Safety Signals and FDA Actions: What the Evidence Shows
A clinician-grade review of tirzepatide (Mounjaro) safety signals, FDA black box warnings, postmarket adverse events, label revisions, and what prescribers should monitor.
Mounjaro in Special Populations: Transplant, HIV, and Other Complex Patient Groups
Evidence-based guide to using Mounjaro (tirzepatide) in special populations including transplant recipients, people living with HIV, older adults, and patients with renal or hepatic impairment.
Does TRICARE Cover Mounjaro? Formulary, Prior Authorization, and Appeal Steps
TRICARE covers Mounjaro (tirzepatide) for type 2 diabetes with prior authorization. Learn formulary tier placement, step therapy requirements, appeal steps for denials, and out-of-pocket cost options for military beneficiaries.
NMN and NR Safety in Adolescents (Ages 12 to 17): What the Evidence Shows
A clinical review of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) safety data relevant to adolescents aged 12 to 17, including pharmacology, risks, and monitoring guidance.
NMN and NR Safety for Adults 30 to 49: What the Clinical Evidence Shows
A clinical review of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) safety data in adults aged 30 to 49, covering dosing, side effects, drug interactions, and monitoring.
Does Cigna Cover NMN/NR (Nicotinamide Mononucleotide/Riboside)?
Find out whether Cigna commercial plans cover NMN or nicotinamide riboside, including prior authorization criteria, formulary tier placement, appeal steps, and cash-pay alternatives.
NMN/NR Cost vs. Alternatives: Comparing NAD+ Precursor Prices and Value
A clinical comparison of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) costs against other NAD+ precursors, niacin, and IV NAD+ infusions, with an evidence-boundary review and dosing context.
NMN and NR Safety in Adults 65 and Older: What the Evidence Actually Shows
A clinical review of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) safety in geriatric adults, covering renal considerations, drug interactions, dosing, and what trials have (and haven't) proven in the 65+ population.
NMN/NR (Nicotinamide Mononucleotide/Riboside): History and Development
A clinical timeline of NMN and NR from the 1906 discovery of NAD+ through modern human trials, FDA regulatory shifts, and ongoing longevity research.
NMN/NR Mechanism of Action: The Full NAD+ Biosynthesis Pathway Explained
A physician-level explanation of how nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) raise NAD+ levels, activate sirtuins and PARPs, and influence metabolic health.
Does State Medicaid Cover NMN or NR (Nicotinamide Mononucleotide/Riboside)?
State Medicaid programs do not cover NMN or nicotinamide riboside. Learn why these NAD precursors fall outside formulary coverage, what alternatives exist, and how to access them affordably.
NMN/NR Monitoring Schedule: Labs, Exams, and Follow-Up Timeline
Evidence-based monitoring schedule for nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) supplementation, including recommended labs, exam intervals, and safety biomarkers reviewed by physicians.
NMN/NR (Nicotinamide Mononucleotide/Riboside) Off-Label Uses With Evidence Levels
A clinical review of NMN and NR off-label applications, from insulin sensitivity to cardiovascular aging, graded by human trial evidence and mechanistic plausibility.
NMN/NR Regulatory Status: US, EU, Canada, and UK Rules for Nicotinamide Mononucleotide and Riboside
NMN supplements sit in a legal gray zone: the FDA excluded NMN from the dietary supplement definition in 2022, and the EU and UK have not authorized it.
NMN/NR Storage, Stability & Shelf Life: Evidence-Based Handling Guide
NMN at 40°C is not stable long-term: unprotected powder loses 15-30% potency over 6 months at 40°C/75% RH, the ICH accelerated stability test standard.
BPC-157 for GI Healing: Off-Label Dosing Protocol, Evidence, and Clinical Considerations
BPC-157 pentadecapeptide is used off-label for GI healing. This evidence-based guide covers dosing protocols, preclinical data, safety signals, and what physicians should know before prescribing.
BPC-157 for Inflammation: Off-Label Evidence, Monitoring, and What Clinicians Need to Know
BPC-157 pentadecapeptide is used off-label for inflammation despite lacking FDA approval. Review the preclinical evidence, proposed mechanisms, monitoring requirements, and safety considerations.